Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.
- Before Adding AI, Fix The Process
- Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance
- How AI Will Reshape Study Start-Up
- Clinical Supply Systems Need IT General Controls
- Medical Affairs: The Missing Link To Oncology Drug Adoption
- Why ING Feels Different
- How Can We Influence Others For Better Outcomes In Clinical Research?
GUEST COLUMNISTS
-
![Teamwork, collaboration-GettyImages-2218614336]( "How Can We Influence Others For Better Outcomes In Clinical Research?")
How Can We Influence Others For Better Outcomes In Clinical Research?Learn how to use the Delphi method to build consensus and drive better decisions in clinical research — even when stakeholders start far apart.
-
![AI making money-GettyImages-2271467935]( "What Will Life Science Orgs Do When The AI Bill Comes Through?")
What Will Life Science Orgs Do When The AI Bill Comes Through?AI is transforming clinical development, but what happens when usage costs spike? Jon Newton explains how to govern it before the bill lands.
-
![Medical quality control-GettyImages-2072996733]( "Clinical Trial Standards — What They Are And Why They're Indispensable")
Clinical Trial Standards — What They Are And Why They're IndispensableClinical trial standards are essential. But to interpret changes, preserve meaning, and assess downstream impact, context is key.
-
![warehouse worker checking barcodes-GettyImages-2265704054]( "Last-Mile Lessons For Depot-To-Site Delivery")
Last-Mile Lessons For Depot-To-Site DeliveryDepot-to-site delivery is more than a courier handoff. See how reconciliation gaps, temperature risks, and mismatched SLAs can turn last-mile issues into trial delays.
-
![jackson AI part 2 using-GettyImages-2192428169]( "Turn AI Visibility Into Action: Build Explanation Layers For Different Stakeholders")
Turn AI Visibility Into Action: Build Explanation Layers For Different StakeholdersAI visibility isn’t just about being found. Ross Jackson coaches sponsors on how to influence AI to provide clear stakeholder pathways for clinical trial involvement.
-
![Medical Hospital Surgery-GettyImages-2210492043]( "5 Ways To Enrich The Clinical Trial Ecosystem")
5 Ways To Enrich The Clinical Trial EcosystemSponsors must treat sites, PIs, and patients as connected parts of a living clinical trial ecosystem. Here are five ways to help make that happen.
-
![Risk Assessment-GettyImages-2192813165]( "The Promise Of MRD-Guided CAR-T Treatment")
The Promise Of MRD-Guided CAR-T TreatmentMinimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.
-
![online question and answer, problem-solving, and digital communication-GettyImages-2241803274]( "Your Trial Shows Up In AI. Now What?")
Your Trial Shows Up In AI. Now What?AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.
CLINICAL TRIAL WHITE PAPERS
-
![Home Diabetes Treatment iStock-1127801655]( "Bringing Clinical Trials To Everyone's Backyard")
Bringing Clinical Trials To Everyone's BackyardLearn how bringing clinical trials to any community around the world is not only possible but also increases patient access and reach and improves recruitment and retention.
-
The Complexities Of Effective Patient Retention In Clinical Trials11/7/2025
Identifying and enrolling the right-fit patients from the outset is essential, but so is implementing comprehensive retention strategies that prioritize patient comfort, trust, and ongoing engagement.
-
Designing More Representative Trials Through Strategic Planning5/28/2025
Strategic planning for representative clinical trials improves outcomes, regulatory alignment, recruitment efficiency, and commercial value by ensuring study populations mirror real-world patients.
-
Pharma R&D Annual Review Supplement: New Active Substances4/15/2026
Last year was by some distance the best year ever in terms of new active substances. Explore the 105 new debuts that easily outstrips that of the previous record holder, 2021’s, 97.
-
A Guide To Digital Endpoints In Major Depressive Disorder3/7/2025
The integration of digital health technologies (DHTs) in clinical trials for Major Depressive Disorder (MDD) is transforming how symptom severity and treatment efficacy are measured.
-
Faster Starts, Stronger Finish: Operational Excellence In NSCLC5/22/2026
In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Biometric Services For Large Pharmaceutical Company7/31/2025
This case exemplifies the effectiveness of flexible staffing solutions in meeting the dynamic needs of the biopharmaceutical industry while maintaining control over project deliverables and timelines.
-
Building A Scalable Oncology Engine In A Dynamic Market6/3/2026
Learn how a top-10 global pharmaceutical company partnered with Medable to rapidly scale the number of oncology trials it could concurrently conduct.
-
Accelerating A Global, FIH ADC Therapy Trial For Lung Cancer11/17/2025
Choose a development partner who can navigate global execution, ADC-specific challenges, and Project Optimus requirements so your first-in-human study is designed and positioned for success.
-
Expanding Access To Post-Market Safety Exams For Cystic Fibrosis Medication1/29/2025
This study highlights the transformative impact of point-of-need care on patient access, focusing on pediatric cystic fibrosis (CF) patients requiring essential eye exams.
-
How A Rare Disease Biotech Replaced Manual Processes With RTSM Software3/26/2026
Discover how a clinical-stage biotech automated its supply chain to protect patient enrollment and eliminate manual errors in a complex, multi-national genetic medicine trial.
-
Maintain Compliance Through Divestiture Without Disrupting Operations6/25/2026
Facing a divestiture? Learn how to protect historical quality records and stay audit-ready throughout the transition.
NEWSLETTER ARCHIVE
- 09.18.26 -- Patients Are Dropping Out — Here's How Sites Are Closing The Gap
- 09.17.26 -- Five Ways To Enrich The Clinical Trial Ecosystem
- 09.16.26 -- Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy
- 09.16.26 -- From Sample Handling To Site Support: What's Powering Trial Success
- 09.15.26 -- Build Explanation Layers For Different Stakeholders
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
![jackson AI part 2 using-GettyImages-2192428169]( "Turn AI Visibility Into Action: Build Explanation Layers For Different Stakeholders")
AI visibility isn’t just about being found. Ross Jackson coaches sponsors on how to influence AI to provide clear stakeholder pathways for clinical trial involvement.
-
![online question and answer, problem-solving, and digital communication-GettyImages-2241803274]( "Your Trial Shows Up In AI. Now What?")
AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.
-
![nurse and patient-GettyImages-1196843513]( "Sustainable Patient Engagement: Your Enrollment And Representation Depend On It")
Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.
FOCUS ON PATIENTS
-
![business man looking through telescope-GettyImages-2215651052]( "Why Oncology Programs Can't Rely On An Inside View Alone")
Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.
-
![Risk Assessment-GettyImages-2192813165]( "The Promise Of MRD-Guided CAR-T Treatment")
Minimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.
-
![pharmacist, service, guidance, patient care-GettyImages-2260105068]( "The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option")
Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.
